Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival
Open Access
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 145, 112411
Abstract
No abstract availableKeywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (200110)
This publication has 42 references indexed in Scilit:
- Increased Beta2-Adrenoceptors in Doxorubicin-Induced Cardiomyopathy in RatPLOS ONE, 2013
- Cell-Based Screening Identifies Paroxetine as an Inhibitor of Diabetic Endothelial DysfunctionDiabetes, 2013
- Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studiesThe Lancet Oncology, 2011
- Adriamycin nephropathy: A model of focal segmental glomerulosclerosisNephrology, 2010
- Modulation of β-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5Heart Failure Reviews, 2010
- Doxorubicin CardiomyopathyCardiology, 2009
- Sertraline Causes Strong Coronary Vasodilation: Possible Relevance for Cardioprotection by Selective Serotonin Reuptake InhibitorsCardiovascular Drugs and Therapy, 2004
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Dose response and toxicity of doxorubicin microspheres in a rat tumor modelAnti-Cancer Drugs, 1992
- Effects of chronic administration of doxorubicin on myocardial beta-adrenergec receptorsLife Sciences, 1986